Could a single cell infusion help newly diagnosed type 1 diabetes patients?

NCT ID NCT05626712

Recruiting now Disease control Sponsor: Creative Medical Technology Holdings Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called CELZ-201 for people recently diagnosed with type 1 diabetes. The treatment involves a one-time infusion of cells from donated tissue into the pancreas. The main goal is to see if it is safe, but researchers will also check if it helps the body keep making its own insulin. Only 18 adults aged 18–35 will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CELZ-201 (perinatal tissue derived cells)
What this could lead to: If it works, this could point toward a way to preserve insulin production in people newly diagnosed with type 1 diabetes, potentially reducing their need for insulin shots.
What could go wrong: This is a very early, small trial (18 people) focused mainly on safety. It is too soon to know if the treatment will actually help control diabetes, and there may be risks from the cell infusion or the procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus type 1 diabetes mellitus 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 1 TYPE 1 DIABETES

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Diabetes Research Institute, University of Miami Miller School of Medicine
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.